Jackson Square Partners LLC grew its stake in shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) by 5.9% during the third quarter, Holdings Channel reports. The institutional investor owned 2,832,601 shares of the specialty pharmaceutical company’s stock after acquiring an additional 158,281 shares during the quarter. Jackson Square Partners LLC owned about 0.08% of AMAG Pharmaceuticals worth $56,652,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. Advisors Asset Management Inc. lifted its holdings in shares of AMAG Pharmaceuticals by 791.6% during the 2nd quarter. Advisors Asset Management Inc. now owns 58,970 shares of the specialty pharmaceutical company’s stock valued at $123,000 after purchasing an additional 52,356 shares in the last quarter. Piedmont Investment Advisors LLC bought a new position in shares of AMAG Pharmaceuticals during the 2nd quarter valued at about $156,000. Meeder Asset Management Inc. lifted its holdings in shares of AMAG Pharmaceuticals by 590.9% during the 2nd quarter. Meeder Asset Management Inc. now owns 8,947 shares of the specialty pharmaceutical company’s stock valued at $174,000 after purchasing an additional 7,652 shares in the last quarter. HighPoint Advisor Group LLC bought a new position in shares of AMAG Pharmaceuticals during the 3rd quarter valued at about $188,000. Finally, NumerixS Investment Technologies Inc lifted its holdings in shares of AMAG Pharmaceuticals by 243.2% during the 2nd quarter. NumerixS Investment Technologies Inc now owns 12,700 shares of the specialty pharmaceutical company’s stock valued at $257,000 after purchasing an additional 9,000 shares in the last quarter.

AMAG has been the topic of several recent analyst reports. ValuEngine cut AMAG Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Friday, September 14th. BidaskClub upgraded AMAG Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, August 14th. B. Riley lifted their price objective on AMAG Pharmaceuticals from $30.00 to $31.00 and gave the company a “buy” rating in a report on Monday, August 6th. Cantor Fitzgerald set a $18.00 price objective on AMAG Pharmaceuticals and gave the company a “hold” rating in a report on Wednesday, September 26th. Finally, Jefferies Financial Group reiterated a “hold” rating and set a $22.00 price objective on shares of AMAG Pharmaceuticals in a report on Friday, August 3rd. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $21.97.

NASDAQ AMAG opened at $18.02 on Wednesday. The company has a market capitalization of $628.89 million, a price-to-earnings ratio of -3.16 and a beta of 0.23. The company has a current ratio of 2.86, a quick ratio of 2.72 and a debt-to-equity ratio of 0.34. AMAG Pharmaceuticals, Inc. has a 52 week low of $11.95 and a 52 week high of $26.10.

AMAG Pharmaceuticals (NASDAQ:AMAG) last released its earnings results on Thursday, November 1st. The specialty pharmaceutical company reported ($1.88) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.77) by ($1.11). The firm had revenue of $122.20 million during the quarter, compared to the consensus estimate of $118.23 million. AMAG Pharmaceuticals had a negative net margin of 6.98% and a negative return on equity of 13.65%. The company’s revenue was down 1.7% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($4.31) EPS. As a group, equities analysts expect that AMAG Pharmaceuticals, Inc. will post -2.85 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This article was posted by Daily Political and is the property of of Daily Political. If you are reading this article on another domain, it was stolen and republished in violation of U.S. & international copyright and trademark laws. The original version of this article can be accessed at https://www.dailypolitical.com/2018/11/21/jackson-square-partners-llc-increases-position-in-amag-pharmaceuticals-inc-amag.html.

AMAG Pharmaceuticals Company Profile

AMAG Pharmaceuticals, Inc, a biopharmaceutical company, manufactures, develops, and commercializes therapeutics for maternal and women's health, anemia management, and cancer supportive care in the United States. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds.

See Also: When is a capital gain realized?

Want to see what other hedge funds are holding AMAG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG).

Institutional Ownership by Quarter for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.